Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Global Clinical Trials Review, H1, 2019

GlobalData's clinical trial report, “Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Global Clinical Trials Review, H1, 2019" provides an overview of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) clinical trials scenario. This report provides top line data relating to the clinical trials on Congenital Adrenal Hyperplasia (Adrenogenital Syndrome). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies mentioned

Neurocrine Biosciences Inc

Simbec-Orion Group Ltd

Spruce Biosciences Inc

Millendo Therapeutics Inc

Novartis AG

Concordia International Rx UK Ltd

Changi General Hospital Pte Ltd

Bristol ...

Neurocrine Biosciences Inc

Simbec-Orion Group Ltd

Spruce Biosciences Inc

Millendo Therapeutics Inc

Novartis AG

Concordia International Rx UK Ltd

Changi General Hospital Pte Ltd

Bristol Laboratories Ltd

IP Group Plc

GCP-Service International Ltd & Co KG

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

GlobalData Clinical Trials Report Coverage 7

Clinical Trials by Region ...

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

GlobalData Clinical Trials Report Coverage 7

Clinical Trials by Region 8

Clinical Trials and Average Enrollment by Country 9

Top Countries Contributing to Clinical Trials in Asia-Pacific 12

Top Five Countries Contributing to Clinical Trials in Europe 13

Top Countries Contributing to Clinical Trials in North America 14

Top Countries Contributing to Clinical Trials in Middle East and Africa 15

Top Countries Contributing to Clinical Trials in Central and South America 16

Clinical Trials by G7 Countries: Proportion of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) to Hormonal Disorders Clinical Trials 17

Clinical Trials by Phase in G7 Countries 19

Clinical Trials in G7 Countries by Trial Status 20

Clinical Trials by E7 Countries: Proportion of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) to Hormonal Disorders Clinical Trials 22

Clinical Trials by Phase in E7 Countries 24

Clinical Trials in E7 Countries by Trial Status 25

Clinical Trials by Phase 26

In Progress Trials by Phase 27

Clinical Trials by Trial Status 28

Clinical Trials by End Point Status 30

Subjects Recruited Over a Period of Time 31

Clinical Trials by Sponsor Type 32

Prominent Sponsors 33

Top Companies Participating in Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials 35

Prominent Drugs 37

Latest Clinical Trials News on Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) 39

Mar 25, 2019: Spruce Biosciences Achieves Proof of Concept in Phase 2 Study of Tildacerfont in Congenital Adrenal Hyperplasia 39

Mar 14, 2019: Millendo Therapeutics announces ENDO 2019 presentation on nevanimibe for classic congenital adrenal ayperplasia 39

Mar 13, 2019: Neurocrine reports positive interim results from CAH trial 39

Mar 08, 2019: Spruce Biosciences Announces Presentation of Positive Topline Data from Phase 2 Study of Tildacerfont (SPR001) in Congenital Adrenal Hyperplasia at the 2019 Annual Meeting of the Endocrine Society (ENDO) 40

Clinical Trial Profile Snapshots 41

Appendix 75

Abbreviations 75

Definitions 75

Research Methodology 76

Secondary Research 76

About GlobalData 77

Contact Us 77

Source 78

List of Tables

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials by Region, 2019* 8

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment ...

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials by Region, 2019* 8

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2019* 12

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 13

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, North America, Top Countries, 2019* 14

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2019* 15

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Central and South America, Top Countries, 2019* 16

Proportion of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) to Hormonal Disorders Clinical Trials, G7 Countries (%), 2019* 17

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20

Proportion of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) to Hormonal Disorders Clinical Trials, E7 Countries (%), 2019* 22

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials by Phase, 2019* 26

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 27

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 28

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 30

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 31

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 32

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 33

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 35

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 37

List of Figures

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials by Region (%), 2019* 8

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials and Average ...

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials by Region (%), 2019* 8

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2019* 12

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 13

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2019* 16

Proportion of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) to Hormonal Disorders Clinical Trials, G7 Countries (%), 2019* 17

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20

Proportion of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) to Hormonal Disorders Clinical Trials, E7 Countries (%), 2019* 22

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials by Phase (%), 2019* 26

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 27

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 28

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 30

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 31

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 32

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 33

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 35

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 37

GlobalData Methodology 76

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports